Ovid Therapeutics Inc.
NASDAQ:OVID
1.19 (USD) • At close October 29, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Ovid Therapeutics Inc. |
Symbool | OVID |
Munteenheid | USD |
Prijs | 1.19 |
Beurswaarde | 84,456,204 |
Dividendpercentage | 0% |
52-weken bereik | 0.68 - 4.1 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir |
Website | https://www.ovidrx.com |
An error occurred while fetching data.
Over Ovid Therapeutics Inc.
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)